Tongzhou Cohort Study

Long-term Impact of Overweight/Obesity and Hypertension on Cardiovascular Risk in Middle-aged and Elderly Adults: A Cohort Study

Long-term Impact of Overweight/Obesity and Hypertension on Cardiovascular Risk in Middle-aged and Elderly Adults

Study Overview

• Status: Active, not recruiting
• Conditions: Hypertension; Obesity
• Intervention / Treatment: Other: No intervention

Detailed Description

Overweight and obesity are major risk factors associated with the development of hypertension, poor blood pressure control, and adverse cardiovascular outcomes. However, evidence regarding the long-term impact of overweight/obesity and hypertension on cardiovascular risk in middle-aged and elderly populations remains limited. Therefore, the present study aims to evaluate the long-term effects of overweight/obesity and hypertension on cardiovascular risk in middle-aged and elderly adults.Additionally, a subgroup analysis will be conducted in participants with sarcopenia to assess the influence of blood pressure on prognosis, exploring potential interactions between muscle loss, hypertension, and cardiovascular outcomes.

• Study Type: Observational
• Enrollment (Actual): 31080

Contacts and Locations

Study Locations

• China
  • Beijing Municipality
    • Beijing, Beijing Municipality, China, 100050
      • Beijing Friendship Hospital, Capital Medical University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 60 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Adults undergoing routine physical examinations at community health service centers in Tongzhou, China.

Description

Inclusion Criteria:

• Ages of ≥ 45 years
• Participants from routine health examinations at Tongzhou Community Health Service Center
• Availability for follow-up until 2026
• No major barriers to provide written consent

Exclusion Criteria:

• NA

Study Plan

How is the study designed?

Number of groups / cohorts

6

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Obese hypertensive group; Patients who were diagnosed with obesity (body mass index (BMI)≥28kg/m2) and hypertension (systolic blood pressure (SBP)/diastolic blood pressure (DBP) ≥ 140/90 mmHg).	Other: No intervention; This is an observational study without any intervention
Overweight hypertensive group; Overweight patients (24 kg/m2≤BMI≤28 kg/m2) diagnosed with hypertension (SBP/DBP≥140/90 mmHg).	Other: No intervention; This is an observational study without any intervention
Lean hypertensive group; Lean patients (BMI ≤ 24 kg/m2) diagnosed with hypertension (SBP/DBP ≥ 140/90 mmHg).	Other: No intervention; This is an observational study without any intervention
Lean normotensive; Lean patients (BMI ≤ 24 kg/m2) diagnosed with normotensive (SBP/DBP < 140/90 mmHg).	Other: No intervention; This is an observational study without any intervention
Overweight normotensive; Overweight patients (24 kg/m2≤BMI≤28 kg/m2) diagnosed with normotensive (SBP/DBP<140/90 mmHg)	Other: No intervention; This is an observational study without any intervention
Obese normotensive; Patients who were diagnosed with obesity (BMI≥28kg/m2) and normotensive (SBP/DBP<140/90 mmHg).	Other: No intervention; This is an observational study without any intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of participants with major adverse cardiovascular events (MACEs)	Percentage of participants with major adverse cardiovascular events (MACEs), including all-cause death, nonfatal myocardial infarction (MI), nonfatal stroke and coronary revascularization.	2021-2026

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of participants with all-cause death	Percentage of participants with cardiovascular, non-cardiovascular and undetermined death.	2021-2026
Percentage of participants with MI	Percentage of participants with fatal and nonfatal MI.	2021-2026
Percentage of participants with stroke	Percentage of participants with fatal and nonfatal stroke.	2021-2026
Percentage of participants undergoing coronary revascularization	Percentage of participants undergoing ischemia- and non-ischemia-driven coronary revascularization.	2021-2026
Change in BP control rate	Change in BP control rate (office BP: SBP < 140 mmHg and DBP < 90 mmHg) from baseline to follow-up.	2021-2026
Change in SBP	Change in SBP from baseline to follow-up.	2021-2026
Change in estimated glomerular filtration rate (eGFR)	Change in estimated glomerular filtration rate (eGFR) in ml/min/1.73m2 from baseline to follow-up.	2021-2026
Change in low-density lipoprotein-cholesterol (LDL-c)	Change in low-density lipoprotein-cholesterol (LDL-c) in mmol/L from baseline to follow-up.	2021-2026
Percentage of participants with Metabolic dysfunction-associated steatotic liver disease (MASLD)	Percentage of participants with Metabolic dysfunction-associated steatotic liver disease.	2021-2026

Collaborators and Investigators

• Sponsor: Beijing Friendship Hospital
• Collaborators: Beijing Tongzhou Yongshun Community Health Service; Beijing Tongzhou Lucheng Community Health Service; Beijing Tongzhou Xuxinzhuang Community Health Service
• Investigators: Principal Investigator: Rongchong Huang, M.D., Beijing Friendship Hospital

Study record dates

Study Major Dates

• Study Start (Actual): July 1, 2016
• Primary Completion (Estimated): July 1, 2026
• Study Completion (Estimated): September 1, 2026

Study Registration Dates

• First Submitted: November 24, 2021
• First Submitted That Met QC Criteria: December 12, 2021
• First Posted (Actual): December 14, 2021

Study Record Updates

• Last Update Posted (Estimated): October 2, 2025
• Last Update Submitted That Met QC Criteria: September 29, 2025
• Last Verified: August 1, 2024

More Information

Terms related to this study

• Keywords: Obesity; Hypertension; Cardiovascular risk
• Additional Relevant MeSH Terms: Vascular Diseases; Cardiovascular Diseases; Nutrition Disorders; Overnutrition; Body Weight; Overweight; Pathological Conditions, Signs and Symptoms; Nutritional and Metabolic Diseases; Signs and Symptoms; Obesity; Hypertension
• Other Study ID Numbers: 2021-P2-163-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No